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Neuroendocrine differentiation (NED) in prostate cancer is a well-recognized phenotypic
change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like)
cells. NE-like cells lack the expression of androgen receptor and prostate specific anti-
gen, and are resistant to treatments. In addition, NE-like cells secrete peptide hormones
and growth factors to support the growth of surrounding tumor cells in a paracrine manner.
Accumulated evidence has suggested that NED is associated with disease progression and
poor prognosis. The importance of NED in prostate cancer progression and therapeutic
response is further supported by the fact that therapeutic agents, including androgen-
deprivation therapy, chemotherapeutic agents, and radiotherapy, also induce NED. We
will review the work supporting the overall hypothesis that therapy-induced NED is a
mechanism of resistance to treatments, as well as discuss the relationship between
therapy-induced NED and therapy-induced senescence, epithelial-to-mesenchymal tran-
sition, and cancer stem cells. Furthermore, we will use radiation-induced NED as a model
to explore several NED-based targeting strategies for development of novel therapeutics.
Finally, we propose future studies that will specifically address therapy-induced NED in the
hope that a better treatment regimen for prostate cancer can be developed.
Keywords: neuroendocrine differentiation, prostate cancer, CREB, ATF2, radiosensitization, radiotherapy, cancer
stem cell, EMT
INTRODUCTION
Prostate cancer is the second leading cause of cancer death among
men in developed countries (1). In 2015, it is estimated that 27,540
men will die from prostate cancer in US according to American
Cancer Society. Most of these deaths are due to the progression
of localized diseases into metastatic, castration-resistant, prostate
cancer (CRPC).
Based on prostate specific antigen (PSA) level, tumor grade, and
the extent of primary tumor in the prostate gland, clinically local-
ized prostate cancer is classified into low-risk (PSA ≤10 ng/ml,
Gleason score ≤6, and stage T1c–T2a), intermediate-risk (PSA
>10 but ≤20 ng/ml, Gleason score 7, or stage T2b), and high-risk
(PSA >20, Gleason score ≥8, or stage T2c) (2, 3). While a major-
ity of low-risk disease is cured with surgery or radiotherapy (RT),
intermediate- and high-risk disease has a relatively high rate of
recurrence following a definitive therapy. For example, approxi-
mately 30–50% of high-risk, clinically localized, prostate cancer
treated with RT develop a biochemical recurrence within 5 years
post-therapy, and about 20% die of prostate cancer within 10 years
(4–7). Given that about 25% of patients are diagnosed with a high-
risk disease at presentation (8), there has been a major effort to
develop a strategy to optimally manage this group of patients in
recent years.
Resistance to RT (radioresistance) can be intrinsic or acquired
(9). Given the heterogeneity of prostate cancer cells, it is likely
that certain cells have intrinsic radioresistance, whereas others
have the ability to acquire radioresistance over the course of RT.
This review discusses the recent advance in our understanding of
radiation-induced neuroendocrine differentiation (NED) and the
implication on RT efficacy, and proposes possible approaches to
addressing radiation-induced NED.
NEUROENDOCRINE DIFFERENTIATION AS A MECHANISM OF
THERAPY RESISTANCE
Normal prostate tissue consists of three types of epithelial cells:
basal cells, luminal cells, and neuroendocrine (NE) cells. Unlike
basal cells and luminal cells, NE cells constitute only <1% of total
epithelial cells, and their physiological role remains unclear (10).
In prostate adenocarcinoma, the presence of an increased number
of neuroendocrine-like (NE-like) cells is observed (10–14). It has
been hypothesized that these NE-like cells may arise from luminal-
type prostate cancer cells by a NED or transdifferentiation process
(15–17). NE-like cells do not proliferate, and lack the expression
of androgen receptor (AR) and PSA.
Clinical observations have suggested that NED correlates with
disease progression and poor prognosis (14, 16, 18–28). Several
mechanisms may account for the impact of NED on prostate can-
cer progression and therapeutic responses. First, NE-like cells do
not proliferate, and thus they function as a dormant phenotype
making NE-like cells particularly resistant to therapies. Second,
NE-like cells express high levels of survival genes such as survivin
and Bcl-2 (29–31), or exhibit alteration in calcium homeostasis
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(32), again conferring resistance to treatments. Third, NE-like cells
secrete a number of peptide hormones and growth factors to sup-
port the growth of surrounding tumor cells in a paracrine manner.
Lastly, NED is a reversible process (33, 34). For example, treatment
of LNCaP cells with cAMP or cAMP-inducing agents induces
NED within a few days (33). Interestingly, removal of cAMP or
cAMP-inducing agents results in either retraction or shedding of
the neuritic processes within 10 h. Also, within 2 days the expres-
sion of neuron specific enolsase (NSE), a biomarker of NE and
NE-like cells, returns to basal levels. Similarly, NED induced by
androgen depletion (e.g., charcoal-stripped fetal bovine serum-
containing medium) can be reversed by culturing cells in normal
serum-containing medium. Based on these observations, there are
two possible pathways by which NED can contribute to disease
progression and therapy failure (Figure 1). One is that NE-like
cells can survive therapeutic interventions and thus contribute to
tumor recurrence if they resume proliferation post treatments.
Second, the presence of NE-like cells supports the growth of sur-
rounding tumor cells in a paracrine manner, thus conferring to
disease progression.
PRE-EXISTING NED VERSUS THERAPY-INDUCED NED IN
PROSTATE CANCER
PRE-EXISTING NED
Although NE-like cells in adenocarcinoma share many charac-
teristics of normal NE cells, they also differ in some aspects.
For example, NE-like cells express some luminal cell markers,
whereas NE cells express some basal cell markers (15). Accumu-
lating evidence favors the hypothesis that NE-like cells come from
a transdifferentiation process of prostate cancer cells, either from
hormone-naïve or CRPC (15). There are numerous stimuli and
FIGURE 1 | Impact of neuroendocrine differentiation on prostate
cancer progression and tumor recurrence. Neuroendocrine differentiation
(NED) can be induced by fractionated ionizing radiation (FIR), cAMP,
androgen-deprivation therapy (ADT), and IL-6 via distinct signaling pathways.
The clinical impact of NED on prostate cancer progression and therapy
response can be twofold. On the one hand, NE-like cells can produce
peptide hormones and growth factors to promote tumor progression. On
the other hand, the dormant and apoptosis-resistant NE-like cells may
resume the ability to proliferate due to the reversibility of NED, and
contribute to treatment failure and tumor recurrence.
agents, which likely activate distinct signaling pathways to induce
NED (15, 35). For example, cAMP signaling may activate the
PKA/CREB signaling pathway to induce NED (33, 36–41), whereas
IL-6-induced NED appears to be mediated by activation of the
PI3K/Etk/Bmx and STAT3 pathways (35, 36, 42–46) (Figure 1).
Interestingly, while EGF may prevent androgen depletion-induced
NED in an MAPK and PI3K/AKT-dependent manner (47), it may
also promote NED in LNCaP cells in an ErbB2-dependnt man-
ner if treated with an inhibitor of the PI3K/AKT pathway such
as LY294002 (48, 49). Because activation of the cAMP signaling
pathway and the PI3K/AKT pathways are often associated with
prostate cancer development and progression, it is very likely that
a subset of cells may undergo NED during prostate cancer develop-
ment and progression. Thus, these NE-like cells are already present
at the time of initial diagnosis of prostate cancer, and this pre-
existing NED confers resistance to subsequent treatments such as
RT, androgen-deprivation therapy (ADT), and chemotherapy (14,
16, 18–28).
THERAPY-INDUCED NED
Therapy-induced NED refers to acquired NED induced by a ther-
apeutic agent. Such therapeutic agents include ADT (50–52) and
docetaxel (23, 53). Recently, it has been shown that enzalutamide
and abiraterone (two recently FDA-approved agents for the treat-
ment of CRPC) can also induce NED and that induced NED is
correlated with poor survival in CRPC patients (54,55). Consistent
with these clinical observations, induction of NED in prostate can-
cer cells by androgen depletion is well established in vitro (34, 47,
56–59) and in prostate cancer xenografts in mice (59–64). Lin et al.
recently reported that a patient-derived xenograft line showed a
complete induction of NED following castration (compared to no
sign of NED prior to castration) (65). These observations provide
convincing evidence that castration does induce NED.
RT CAN ALSO INDUCE NED
While working on the isolation of radiation-resistant sublines after
a fractionated RT regimen (2 Gy/day, 5 days/week), we unexpect-
edly found the display of apparent neurite outgrowth by irradiated
cells after a 4-week fractionated ionizing radiation (FIR) (66).
Immunoblotting analysis confirmed that these cells express high
levels of NE markers chromogranin A (CgA) and NSE, indi-
cating that FIR also induces NED in vitro. Furthermore, it was
observed that FIR-induced LNCaP xenograft tumors to undergo
NED in nude mice, which displayed a four to fivefold increase of
serum CgA after 4-week FIR (67). Consistent with this observa-
tion, in a pilot clinical study, we measured serum CgA in nine
patients who were treated with RT, and found that four out of
nine patients showed 1.5- to 2.2-fold increase in serum CgA after
7-week RT (67). Similarly, Lileby et al. also found that a sub-
set of prostate cancer patients treated with RT showed elevated
serum CgA levels 3 months after the treatment (21). However,
these pilot clinical studies have neither addressed the issue of
whether RT-induced CgA elevation correlates with RT failure nor
have they established the relationship between the disease status
and the extent of serum CgA elevation. Nevertheless, it is clear that
NED can be induced by clinical therapeutic agents including RT
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(acquired NED), and therapy-induced NED may represent one of
the mechanisms leading to treatment failure.
THE RELATIONSHIP BETWEEN NE-LIKE CELLS, CANCER
STEM CELLS, SENESCENT CELLS, AND
EPITHELIAL-MESENCHYMAL TRANSITION
Based on the expression of marker proteins in NE cells, lumi-
nal cells, and basal cells, it was suggested that NE-like cells arise
from prostate cancer cells by a process of NED or transdifferenti-
ation (15). However, there is also evidence suggesting that NE-like
cells are derived from neural crest cells or stem cells as extensively
reviewed by Conteduca et al. (17). Palapattu et al. examined the
expression of cancer stem cell marker CD44 in LNCaP, DU-145,
and PC-3 cells (68), and revealed that CD44 is only expressed in
cells that are positive for NE markers. Consistent with this obser-
vation, the correlation between CD44 expression and NE markers
(NSE and CgA) was also observed in prostate cancer tissues. Inter-
estingly, 100% of prostatic small cell NE carcinomas, an aggressive
variant of prostate cancer that is composed of highly proliferat-
ing NE cells, have CD44 expression, whereas its expression was
detectable only in a minority of small cell NE carcinoma from
other organs. This observation raised an interesting possibility
that CD44 expression may be a useful biomarker to distinguish the
origin of prostate small cell NE carcinoma from NE carcinoma in
other organs. Because CD44 positive cells are capable of generating
CD44 negative cells, are highly tumorigenic, and express several
“stemness” genes (69), these findings support the hypothesis that
CD44 positive NE-like cells are prostate cancer cell stem cells.
Recently, Kyjacova et al. used clinically relevant FIR to irradi-
ate four human prostate cancer cell lines, and observed that there
are two populations of survived cells: one is adherent, senescent-
like cells, and the other is non-adherent, anoikis-resistant stem
cell-like cells (70). However, since the authors did not examine
the expression of NE markers, it remains unknown whether one
or both populations also express NE markers. We previously iso-
lated several sublines from irradiated LNCaP cells that lost the
expression of CgA and NSE (66). All three sublines could not
be induced to undergo NED by FIR. Because NED, cancer stem
cells, and epithelial–mesenchymal transition (EMT) share similar
properties (17), it would be interesting to examine whether these
sublines exhibit properties of cancer stem cells, senescent cells,
and/or mesenchymal cells. Nonetheless, these observations sug-
gest that FIR treatment may selectively enrich the population of
cancer stem cells or induce NED, senescence, and/or EMT. Several
mechanisms may account for this. First, NE-like cells, cancer stem
cells, and EMT or senescent cells may have the same origin (e.g.,
stem cells); thus, the type of phenotypic changes may depend on
the type of stimuli. Second, NED, cancer stem cells, and EMT or
senescence may have a significant overlap of signaling molecules
that are required for the development and maintenance of each of
these phenotypic changes (17). For example, expression of Snail,
a major transcription factor implicated in the induction of EMT,
also induces NED in LNCaP cells (71). Third, these phenotypic
changes share common inducers, which could lead to induction
of NED, stemness, EMT, or senescence. In fact, stress signaling,
such as hypoxia, can induce both NED (72) and EMT (73), as
well as enrich the cancer stem cell subpopulation (74). Finally,
considering cell heterogeneity, the cellular populations may con-
sist of all of these cell types that are induced by distinct stimuli.
Future cell lineage analysis and single cell analysis will likely pro-
vide insight into the origin of NE-like cells and their relationship
with other cell types.
MECHANISM OF RADIATION-INDUCED NED
To study how NED is regulated at the transcriptional level,
we examined the subcellular localization of ATF2 and observed
increased cytoplasmic localization (66). ATF2 is a member of acti-
vator protein 1 (AP-1) family of proteins (75, 76). We discovered
that ATF2 is a nucleocytoplasmic shuttling protein that possesses
two nuclear import motifs and two nuclear export motifs (77, 78).
ATF2 shuttles in LNCaP cells and IR impairs its nuclear import
(66). Given that ATF2 belongs to the ATF/CREB family, and CREB
is known to both regulate CgA transcription (79) and act down-
stream of the cAMP signaling (20, 80), we examined the expression
and activation of CREB, and found that IR activated CREB as
well as increased nuclear localization of phosphorylated CREB
at Ser133 (66). These results suggest that CREB is a transcrip-
tional activator of NED while ATF2 is a transcriptional repressor
of NED, and that FIR tilts the balance between CREB and ATF2,
leading to cell differentiation (Figure 2). Indeed, expression of a
constitutively activated CREB is sufficient to induce NED, whereas
expression of a constitutively nuclear-localized ATF2 (nATF2) can
antagonize CREB-induced NED (66). Consistent with the con-
verse roles of CREB and ATF2, nATF2, or a non-phosphorylatable
CREB (CREB133A) also inhibits FIR-induced NED. Likewise,
we recently established stable cell lines expressing several CREB
short hairpin RNAs (shRNAs), and found that CREB knockdown
significantly inhibited FIR-induced neurite outgrowth and NSE
FIGURE 2 |Transcriptional regulation of radiation-induced
neuroendocrine differentiation in prostate cancer cells. CREB and ATF2
belong to the same CREB/ATF family transcription factors to regulate gene
transcription by binding to the same cAMP response element (CRE). ATF2
constantly shuttles as a monomric form between the nucleus and
cytoplasm in prostate cancer cells, and its nuclear regulation is tightly
regulated. CREB acts as a transcriptional activator and ATF2 functions as a
transcriptional repressor of NED in prostate cancer cells. Fractionated
ionizing radiation (FIR) induces NED by activating CREB and impairing the
nuclear import of ATF2.
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expression (81). However, CgA expression was not inhibited which
was surprising given that CREB can activate CgA transcription.
Because the CREB family members form different homodimers
or heterodimers, the inability of CREB knockdown to inhibit
CgA expression may be explained by functional compensation
of other dimeric complexes. To overcome this, we established
another stable cell line that has inducible expression of ACREB, a
dominant negative CREB in which the basic region is replaced by
acidic amino acids hence deficient in DNA-binding. This ACREB
forms a dimeric complex not only with CREB but also with other
CREB family members, exhibiting a potent inhibitory effect on the
expression of CREB target genes (82, 83). Indeed, ACREB expres-
sion increased radiation-induced cell death by more than 70%
in the setting of 40 Gy FIR treatment. Importantly, expression of
ACREB both during the first 2 weeks (acquisition of radioresis-
tance) and during the second 2 weeks (acquisition of NED phase)
increased FIR-induced cell death (81). This result not only demon-
strates the critical role of CREB in FIR-induced NED but also
provides evidence that targeting either phase could be an effective
approach to developing novel radiosensitizers.
MULTIPLE PHASES OF RADIATION-INDUCED NED
Fractionated ionizing radiation-induced NED differs from andro-
gen depletion- and cAMP-induced NED in that cancer cells must
survive from the treatment first. Unlike cAMP- and androgen
depletion-induced NED in which almost all LNCaP cells can be
induced to differentiate into NE-like cells, we observed that cell
growth was largely inhibited during the first week of irradia-
tion, and increased cell death became apparent during the second
week of irradiation. However, little cell death was observed start-
ing from the third week onward. Instead, cells began to show
neurite outgrowth and cell body became smaller. With continued
irradiation, cells showed extended neurite outgrowth (66). Upon
4 weeks of irradiation, almost all survived cells differentiated into
NE-like cells and continued irradiation for another 3 weeks did
not induce cell death. Similar processes were observed in DU-145
and PC-3 cells, though the extent of NED appears to be less than
LNCaP cells (67). These observations suggest that FIR-induced
NED constitutes several distinct phases: acquisition of radiore-
sistance during the first 2 weeks, acquisition of NED during the
second 2 weeks, maintenance of NED during the last 3 weeks, and
reversal to the proliferating state after the completion of the FIR
treatment (Figure 3).
STRATEGIES TARGETING RADIATION-INDUCED NED
A number of approaches have been attempted to target NE-like
cells by either blocking secreted neuropeptide-mediated effects
or inhibiting the survival signaling pathways in NE-like cells
(17). However, the clinical effect of these therapeutic maneuvers
remains unclear. Because NED can be induced by a variety of
stimuli and therapeutic agents, the underlying molecular mecha-
nisms of NED need to be thoroughly investigated so that targeted
therapies can be developed accordingly. This is particularly impor-
tant for therapy-induced NED. Further, recurrent tumors derived
from therapy-induced NE-like cells may behave differently. For
example, RT- and chemotherapy-induced NED involves a clonal
selection, and likely reprograming of survival cells. These cells are
likely cross-resistant to other treatments (66).
Using radiation-induced NED as a model, we hypothesize here
that two complementary directions could be pursued to develop
novel therapeutics. One is to identify targets and pathways that
are specific for the acquisition of radioresistance and NED, and
the other is to identify molecules that are critical for the mainte-
nance of NE-like phenotype. In addition, developments of agents
FIGURE 3 | Process and targeting strategies of radiation-induced
neuroendocrine differentiation in prostate cancer cells. Shown is a
schematic view of several distinct phases of fractionated ionizing
radiation (FIR)-induced NED in prostate cancer cells (PCa). The critical
role of CREB in the acquisition of radioresistance and NED phases has
been demonstrated, and identification of upstream regulators of CREB
may lead to development of novel radiosensitizers. Targeting NE-like
cells and inhibiting the reversal of the “dormant” NE-like cells to a
proliferating state could also be clinically useful. Further, profiling
radioresistant recurrent prostate cancer cells may allow identification of
molecules contributing to cross-resistance of recurrent prostate cancer
after radiotherapy failure, and ultimately may lead to the development
of novel therapeutic agents for the treatment of recurrent prostate
tumors.
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that inhibit the reversal of NE-like cells or target recurrent tumors
after RT failure should also be considered.
TARGETING ACQUISITION OF RADIORESISTANCE AND
DIFFERENTIATION PHASES
Because NED can be induced by a variety of stimuli via activa-
tion of distinct mechanisms, targeting specific signaling pathways
downstream of a particular inducer is a reasonable strategy. Appli-
cation of such targeting agents (applied as either a single agent
or a combination of multiple agents) would therefore inhibit
therapy-induced NED. In the case of RT-induced NED, we have
demonstrated that the CREB signaling is critical for FIR-induced
NED (66, 67). To determine whether targeting RT-induced NED
can be explored to develop a novel radiosensitizer, we established
doxycycline-inducible expression system to diminish CREB activ-
ity by expressing either ACREB, a dominant negative mutant of
CREB, or shRNAs to knockdown CREB. The availability of these
two inducible CREB targeting approaches allowed us to specifically
test whether targeting CREB during the first 2 weeks or during
the second 2 weeks can sensitize prostate cancer cells to radiation.
Our results showed that targeting CREB during either phase can
increase FIR-induced cell death (81). This finding not only con-
firms that CREB is critical for FIR-induced NED but also suggests
that targeting FIR-induced NED can sensitize prostate cancer cells
to radiation. Since several CREB targeting agents are being devel-
oped (84), it would be interesting to test whether these agents are
effective in inhibiting FIR-induced NED. Furthermore, identifica-
tion of upstream regulators, e.g., protein kinases, could provide an
important approach to targeting FIR-induced NED. In conclusion,
this type of targeting agents can be developed as radiosensitizers
by targeting either the acquisition of radioresistance, NED phase,
or both phases.
TARGETING NE-LIKE CELLS
Because NE-like cells do not proliferate and rather stay as “dor-
mant” cells, cytotoxic chemotherapeutic agents may not be effec-
tive. It is therefore necessary to understand how these “dormant”
cells survive and maintain their phenotype. It is possible that an
autocrine pathway confers cell survival and would be a potential
target for therapeutics. Alternatively, we may target the survival
pathway. For example, NE-like cells often overexpress survivin
(29), and several survivin-targeting agents have been developed
(85). It would be interesting to determine if targeting survivin can
induce apoptosis of therapy-induced NE-like cells.
INHIBITING THE REVERSAL OF NE-LIKE CELLS
One of the potential impact of NED on tumor recurrence is its
reversibility. Like cAMP- and androgen depletion-induced NED
(33, 34, 58), FIR-induced NED may also be reversible (66). The
molecular mechanisms underlying this process remain unclear.
However, inhibiting the reversal of NE-like cells to a proliferating
state may be clinically useful if the reversibility of NE-like cells
does occur in prostate cancer patients.
TARGETING RECURRENT PROSTATE CANCER CELLS
Treatment of recurrent prostate cancer remains a major challenge.
A therapy for recurrent tumor is variable, and depends on the
type of primary treatment. For example, a treatment strategy for
recurrent prostate cancer after RT failure is different from that
for recurrent prostate cancer after surgery. This is because recur-
rent prostate cancer after RT has undergone genetic and epigenetic
changes under the selective pressures, and may be cross-resistant
to other treatments. Consistent with this notion, isolated radiore-
sistant sublines after 40 Gy of FIR are indeed cross-resistant to
androgen depletion and docetaxel (66). Given that 30–50% of
high-risk and 10% of low-risk prostate cancer recur after RT, it is
urgently needed to develop agents that can specifically target recur-
rent prostate cancer after RT failure. Because the recurrent tumor is
composed of heterogeneous cells, including NE-like cells or cancer
stem cells as discussed above, comparative analysis of genetic and
epigenetic changes as well as signaling pathways between multiple
radioresistant sublines and parental cells may lead to identification
of molecular alterations that are common to all recurrent cells. If
identified, molecular alterations could be validated with recur-
rent prostate cancer specimens, and developing novel therapeutics
targeting specifically for RT-failed recurrent prostate cancer may
become possible.
FUTURE PERSPECTIVES
ANIMAL MODELS TO STUDY THE IMPACT OF NED IN PROSTATE
CANCER PROGRESSION AND THERAPEUTIC RESPONSE
The impact of NED on prostate cancer progression has been
well demonstrated in vivo. It was shown that the implantation
of NE mouse prostate allograft (NE-10) in nude mice bearing
LNCaP xenograft tumors on the opposite flank can support the
growth of LNCaP xenograft tumors under castration condition
(86). This study provides compelling evidence that factors secreted
by NE tumors are sufficient to support the growth of prostate
tumors under castration condition (86). Consistent with this,
Deeble et al. elegantly demonstrated again in castrated condition
that coinjection of the constitutively activated protein kinase A
subunit-induced NE-like cells and LNCaP cells into nude mice
enhanced tumor growth (38). These studies corroborated in vitro
findings that conditioned medium from NE-like culture can stim-
ulate the growth of prostate cancer cells (38, 87), and that secreted
mitogenic neuropeptides such as neurotensin are critical for the
stimulation of tumor cell growth (33, 36, 87). Interestingly, Valerie
et al. also showed that treating prostate cancer cells expressing
high levels of neurotensin receptor 1 (NTR1) with a selective
NTR1 antagonist SR48692 sensitizes prostate cancer cells to ion-
izing radiation. Thus, secreted neurotensin from NE-like cells not
only promotes prostate cancer cell growth but also confers the
surrounding tumor cells radioresistance. Although these studies
provide evidence that secreted neuropeptides and growth factors
from NE-like cells in vivo can promote prostate cancer progres-
sion and alter therapeutic responses, these findings are limited
to established cell lines in immunocompromised mice and thus
further research must be done with a better model system.
While many genetically engineered mouse (GEM) models have
been established to study the development, progression, and thera-
peutic responses of prostate cancer (88), a GEM model that allows
for the elucidation of the impact of NED on prostate cancer pro-
gression and therapeutic response is unavailable. By transgenically
overexpressing SV40 large T antigen, a TRAMP mouse model was
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established, which has a high incidence of NE tumor arising from
prostate with a high potential to metastasize to lung, liver, and
other tissues (89). The TRAMP mouse model is more representa-
tive of human NE carcinoma, a rare type of prostate cancer present
at initial clinical presentation or in some ADT-treated setting (88).
Recently, Qi et al. found that knockout of Siah2, a ubiquitin lig-
ase, completely suppresses the development of NE tumors in the
background of TRAMP (90), demonstrating a critical role of this
E3 ligase in the development of NE tumors. Molecular analysis
further revealed that HIF-1α, which is stabilized by Siah2, medi-
ates the effect of Siah2 to selectively regulate, in combination with
FoxA2, the expression of HIF target genes that are required for or
involved in the development of NE tumor. Although these stud-
ies provide genetic evidence that Siah2, HIF-1α, and FoxA2 are
required for the regulation of NE tumor development at the tran-
scription level, the TRAMP mouse model does not permit the
analysis of the impact of pre-existing and therapy-induced focal
NED on disease progression and therapeutic response. Given that
castration-induced NED also occurs in other GEM models (91,
92), it would be interesting to test if FIR also induces NED in these
GEM models. Further, innovative approaches (e.g., inducible NED
mouse models, chemical probes) that allow manipulation of NE-
like cells or NED in these GEM models will likely facilitate the
study of NED impact on prostate cancer progression and radia-
tion response. As castration-induced NED has also been reported
in patient-derived xenograft model system (65), infecting the cells
with lentiviruses (that can inducibly destroy NE-like cells during
the course of FIR treatment) will similarly permit the study of
acquired NED in radio-responsiveness.
CLINICAL DIAGNOSIS OF NED IN PROSTATE CANCER PATIENTS
Traditionally, the proteins such as CgA, NSE, synaptophin, and
others that are expressed by NE-like and NE cells are used as bio-
markers to identify NE-like or NE cells in tissue specimens using
immunohistochemistry. However, analysis is often confounded by
various factors including a sampling issue, leading to conflict-
ing outcomes. Thus, it is generally felt that immunohistochemical
analysis may not accurately represent the status of NED in a given
patient. To overcome this, serum biomarkers have been used and
their correlation to NED in tissues have been examined. It was
found that CgA is the best biomarker to reflect NED in tissue
(93). To date, serum CgA has been used to monitor ADT-induced
NED and chemotherapy-induced NED (23, 24, 27, 53–55, 94, 95).
We and others have also observed serum CgA elevation in some
patients who were treated with RT (21, 67). Because prostate can-
cer cells express a basal level of CgA, and activation of transcription
factors (e.g., CREB) may also lead to increased synthesis of CgA,
measurement of individual biomarkers may not accurately reflect
the status of NED in tissues. In addition, obtaining a biopsy for the
examination of NED in cancer tissues in post-RT setting is very
challenging. Thus, it is very desirable to develop new methods that
can reliably diagnose NED in cancer tissues. One approach is to
test whether circulating tumor cells can be used to monitor NED
in patients in addition to serum CgA measurement. Alternatively,
measurement of multiple biomarkers may be necessary for a more
accurate diagnosis. One example is the ratio of CgA/PSA. Mea-
surement of serum CgA in irradiated xenograft tumors revealed
that the ratio of serum CgA/PSA might provide a better prediction
of NED (67). Given that NE-like cells are PSA-low or negative and
can secrete CgA, future research should focus on their relationship
and the correlation with clinical outcomes.
POTENTIAL IMPACT OF CURRENT TREATMENT MODALITIES ON
RADIOTHERAPY-INDUCED NED
Evaluation of current treatment modalities for locally advanced
diseases
Locally advanced, high-risk, prostate cancer currently poses ther-
apeutic challenges. Currently, the standard management for this
group of patients is a combined treatment of RT plus ADT. The
rationale for combining RT with ADT was based on the fact
that both treatments can kill cancer cells or suppress cancer cell
growth, and that the combination may lead to a synergistic effect.
Indeed, several phase III clinical studies have demonstrated that RT
plus ADT provides a survival benefit, in comparison with either
RT or ADT alone (4, 96–99). The rationale for adding ADT in
the RT setting is that ADT can eliminate androgen-dependent
clones, potentiate the tumoricidal effect of RT, and may erad-
icate micrometastatic disease (96). However, whether ADT can
radiosensitize prostate cancer cells is unknown. In fact, in vitro
studies using LNCaP cells suggest that androgen depletion did not
radiosensitze LNCaP cells in clonogenic assays, though apparent
additive effect was observed (100). Given that ADT induces NED
in a subpopulation of cancer cells (50–52), it would be necessary
to evaluate the impact of this combined therapeutic approach on
therapy-induced NED, in comparison to a monotherapy setting
(ADT or RT alone). Ideally, developing novel therapeutic agents
that not only sensitize prostate cancer cells to RT but also inhibit
therapy-induced NED would be ideal and likely initiate a paradigm
shift for future management of prostate cancer.
Impact of new treatment modalities on RT-induced NED
Radiotherapy is one of the main curative modalities for localized
prostate cancer. Advances have been made to improve the efficacy
of RT in recent years. These include a dose-escalation strategy,
a hypofractionation regimen, an incorporation of chemotherapy,
and a new RT modality such as high-dose-rate brachytherapy and
proton therapy (101–108). Although biological, physical, and clin-
ical rationales clearly support the use of these treatment modali-
ties, their impact on radiation-induced NED remains unstudied. It
is worth mentioning that all nine patients enrolled in our pilot clin-
ical study were treated with proton therapy (67). As such, it could
be critical to compare the effect of various other RT protocols or
modalities on radiation-induced NED. Because FIR-induced NED
is completed by a 4-week of irradiation, a dose-escalation strategy
over a protracted course likely has a minimal effect on radiation-
induced NED. However, other treatment strategies such as an
ultra-hypofractionation regimen (e.g., five treatments over 1–
2 weeks) or high-dose-rate brachytherapy (given over 1–2 weeks)
may have less extent of radiation-induced NED. Also, proton ther-
apy may have less degree of radiation-induced NED, as it has a
higher relative biological effectiveness in comparison to a con-
ventional photon beam. The decrease in radiation-induced NED
may, in turn, translate to a clinical benefit with improved treat-
ment outcomes. On a translational research perspective, it would
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be worthwhile to determine whether the observed clinical ben-
efit correlates with the extent of radiation-induced NED. If so,
this would provide a biological rationale for exploring different
RT regimens or modalities aiming to minimize radiation-induced
NED and may also allow for reduction or possible elimination of
the use of adjuvant ADT in RT setting.
CONCLUSION
Although NED has been a well-recognized phenotypic change in
prostate cancer, its impact on prostate cancer progression and
therapeutic responses has only recently gained significant atten-
tion. Several studies have provided compelling evidence that pre-
existing NED confers resistance to treatments such as RT. However,
the impact of therapy-induced NED on disease progression and
treatment failures has not been rigorously studied. Using FIR-
induced NED as a model system, we have provided evidence
that targeting FIR-induced NED is an effective radiosensitizing
approach. Future research should be directed at understanding
the molecular mechanisms by which FIR induces NED and confers
acquired radioresistance as well as tumor recurrence. With the use
of appropriate animal models, implementation of new technolo-
gies as well as methodologies to diagnose RT-induced NED and
better understanding of the biological effect of novel treatment
modalities, we hope that a better RT strategy will be developed
and implemented in clinical practice in the future.
ACKNOWLEDGMENTS
We would like to thank many collaborators who have contributed
to the study of radiation-induced neuroendocrine differentia-
tion in prostate cancer cells in the Hu lab. The prostate cancer
research projects in the Hu lab have been supported by grants from
U.S. Army Medical Research Acquisition Activity, Prostate Cancer
Research Program (PC073098, PC11190, and PC120512), Purdue
University Center for Cancer Research Small Grants Program, and
the Indiana Clinical and Translational Science Institute funded, in
part, by RR-25761 from the National Institutes of Health, National
Center for Research Resources, Clinical and Translational Sciences
Award. DNA sequencing was conducted in the Purdue Univer-
sity Center for Cancer Research Genomic Core Facility Supported
by NCI CCSG CA23168 to Purdue University Center for Cancer
Research.
REFERENCES
1. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treat-
ment and survivorship statistics, 2012. CA Cancer J Clin (2012) 62(4):220–41.
doi:10.3322/caac.21149
2. D’Amico AV. Risk-based management of prostate cancer. N Engl J Med (2011)
365(2):169–71. doi:10.1056/NEJMe1103829
3. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA,
et al. Biochemical outcome after radical prostatectomy, external beam radia-
tion therapy, or interstitial radiation therapy for clinically localized prostate
cancer. JAMA (1998) 280(11):969–74. doi:10.1001/jama.280.11.969
4. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM,
et al. Long-term survival after radical prostatectomy versus external-beam
radiotherapy for patients with high-risk prostate cancer. Cancer (2011)
117(13):2883–91. doi:10.1002/cncr.25900
5. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA,
et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer
treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003)
57(4):915–28. doi:10.1016/S0360-3016(03)00632-1
6. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al.
Comparison of conventional-dose vs high-dose conformal radiation therapy
in clinically localized adenocarcinoma of the prostate: a randomized controlled
trial. JAMA (2005) 294(10):1233–9. doi:10.1001/jama.294.10.1233
7. D’Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate
cancer recurrence in men treated with radiation alone or in conjunction with
combined or less than combined androgen suppression therapy. J Clin Oncol
(2008) 26(18):2979–83. doi:10.1200/JCO.2007.15.9699
8. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin (2010)
60(5):277–300. doi:10.3322/caac.20073
9. Harrington K, Jankowska P, Hingorani M. Molecular biology for the radiation
oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol
(R Coll Radiol) (2007) 19(8):561–71. doi:10.1016/j.clon.2007.04.009
10. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate
cancer: implications for new treatment modalities. Eur Urol (2005)
47(2):147–55. doi:10.1016/j.eururo.2004.09.007
11. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Mor-
phogenesis, proliferation and androgen receptor status. Ann Oncol (2001)
12(Suppl 2):S141–4. doi:10.1023/A:1012454926267
12. di Sant’Agnese PA. Neuroendocrine differentiation in prostatic carcinoma:
an update on recent developments. Ann Oncol (2001) 12(Suppl 2):S135–40.
doi:10.1023/A:1012402909428
13. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phe-
notype in prostate cancer: basic and clinical aspects. J Endocrinol Invest (2005)
28(11 Suppl):141–5.
14. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP. Clinical impli-
cations of neuroendocrine differentiation in prostate cancer. Prostate Cancer
Prostatic Dis (2007) 10(1):6–14. doi:10.1038/sj.pcan.4500922
15. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells:
neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr
Relat Cancer (2007) 14(3):531–47. doi:10.1677/ERC-07-0061
16. Cindolo L, Cantile M,Vacherot F, Terry S, de la Taille A. Neuroendocrine differ-
entiation in prostate cancer: from lab to bedside. Urol Int (2007) 79(4):287–96.
doi:10.1159/000109711
17. Conteduca V, Aieta M, Amadori D, De Giorgi U. Neuroendocrine differentia-
tion in prostate cancer: current and emerging therapy strategies.Crit Rev Oncol
Hematol (2014) 92(1):11–24. doi:10.1016/j.critrevonc.2014.05.008
18. Huang J, Wu C, di Sant’Agnese PA, Yao JL, Cheng L, Na Y. Function and molec-
ular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol
Histol (2007) 29(3):128–38.
19. Daneshmand S, Quek ML, Pinski J. Neuroendocrine differentiation in prostate
cancer. Cancer Ther (2005) 3:383–96.
20. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate can-
cer. Crit Rev Eukaryot Gene Expr (2004) 14(4):287–300. doi:10.1615/
CritRevEukarGeneExpr.v14.i4.40
21. Lilleby W, Paus E, Skovlund E, Fossa SD. Prognostic value of neuroendocrine
serum markers and PSA in irradiated patients with pN0 localized prostate
cancer. Prostate (2001) 46(2):126–33. doi:10.1002/1097-0045(20010201)46:
2<126::AID-PROS1016>3.3.CO;2-Z
22. Krauss DJ, Hayek S, Amin M, Ye H, Kestin LL, Zadora S, et al. Prognostic signif-
icance of neuroendocrine differentiation in patients with Gleason score 8-10
prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys
(2011) 81(3):e119–25. doi:10.1016/j.ijrobp.2010.12.064
23. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Indepen-
dent prognostic role of circulating chromogranin A in prostate cancer patients
with hormone-refractory disease. Endocr Relat Cancer (2005) 12(1):109–17.
doi:10.1677/erc.1.00876
24. Khan MO, Ather MH. Chromogranin A – serum marker for prostate cancer.
J Pak Med Assoc (2011) 61(1):108–11.
25. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroen-
docrine differentiation in the progression of prostate cancer. Int J Urol (2009)
16(1):37–44. doi:10.1111/j.1442-2042.2008.02175.x
26. Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, et al. Prognos-
tic significance of neuroendocrine expression in lymph node-positive prostate
cancer. Urology (2006) 67(6):1247–52. doi:10.1016/j.urology.2005.12.009
27. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, et al. Prog-
nostic significance of plasma chromogranin a levels in patients with hormone-
refractory prostate cancer treated in cancer and leukemia group B 9480 study.
Urology (2005) 66(2):386–91. doi:10.1016/j.urology.2005.03.040
www.frontiersin.org April 2015 | Volume 5 | Article 90 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hu et al. Radiation-induced neuroendocrine differentiation in prostate cancer
28. Krauss DJ, Amin M, Stone B, Ye H, Hayek S, Cotant M, et al. Chromo-
granin A staining as a prognostic variable in newly diagnosed Gleason score
7-10 prostate cancer treated with definitive radiotherapy. Prostate (2014)
74(5):520–7. doi:10.1002/pros.22771
29. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells
in human prostate over-express the anti-apoptosis protein survivin. Prostate
(2001) 48(1):7–15. doi:10.1002/pros.1076
30. Gong J, Lee J, Akio H, Schlegel PN, Shen R. Attenuation of apoptosis by
chromogranin A-induced Akt and survivin pathways in prostate cancer cells.
Endocrinology (2007) 148(9):4489–99. doi:10.1210/en.2006-1748
31. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 proto-oncogene expression
in prostate cancer and its relationship to the prostatic neuroendocrine cell.
Arch Pathol Lab Med (1994) 118(6):616–8.
32. Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bon-
nal JL, et al. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-
differentiated prostate cancer cells. Cell Death Differ (2004) 11(3):321–30.
doi:10.1038/sj.cdd.4401375
33. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine
characteristics by prostate tumor cells is reversible: implications for prostate
cancer progression. Cancer Res (1999) 59(15):3821–30.
34. Dayon A, Brizuela L, Martin C, Mazerolles C, Pirot N, Doumerc N, et al. Sphin-
gosine kinase-1 is central to androgen-regulated prostate cancer growth and
survival. PLoS One (2009) 4(11):e8048. doi:10.1371/journal.pone.0008048
35. Zelivianski S,Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways
for transdifferentiation of human prostate cancer cells into neuroendocrine-
like phenotype. Biochim Biophys Acta (2001) 1539(1–2):28–43. doi:10.1016/
S0167-4889(01)00087-8
36. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic
AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP
prostate tumor cells. Mol Cell Biol (2001) 21(24):8471–82. doi:10.1128/MCB.
21.24.8471-8482.2001
37. Merkle D, Hoffmann R. Roles of cAMP and cAMP-dependent protein kinase
in the progression of prostate cancer: cross-talk with the androgen receptor.
Cell Signal (2011) 23(3):507–15. doi:10.1016/j.cellsig.2010.08.017
38. Deeble PD, Cox ME, Frierson HF Jr, Sikes RA, Palmer JB, Davidson RJ, et al.
Androgen-independent growth and tumorigenesis of prostate cancer cells are
enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer
Res (2007) 67(8):3663–72. doi:10.1158/0008-5472.CAN-06-2616
39. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, et al. Ter-
minal neuroendocrine differentiation of human prostate carcinoma cells in
response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A (1994)
91(12):5330–4. doi:10.1073/pnas.91.12.5330
40. Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, et al. p21-Activated
kinase 4 promotes prostate cancer progression through CREB.Oncogene (2013)
32(19):2475–82. doi:10.1038/onc.2012.255
41. Cox ME, Deeble PD, Bissonette EA, Parsons SJ. Activated 3’,5’-cyclic AMP-
dependent protein kinase is sufficient to induce neuroendocrine-like dif-
ferentiation of the LNCaP prostate tumor cell line. J Biol Chem (2000)
275(18):13812–8. doi:10.1074/jbc.275.18.13812
42. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differ-
entiation in prostate cancer cells. Prostate (2000) 42(3):186–95. doi:10.1002/
(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E
43. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 under-
goes transition from growth inhibitor associated with neuroendocrine dif-
ferentiation to stimulator accompanied by androgen receptor activation dur-
ing LNCaP prostate cancer cell progression. Prostate (2007) 67(7):764–73.
doi:10.1002/pros.20553
44. Wang Q, Horiatis D, Pinski J. Inhibitory effect of IL-6-induced neuroen-
docrine cells on prostate cancer cell proliferation. Prostate (2004) 61(3):253–9.
doi:10.1002/pros.20106
45. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate
cancer xenografts in mice by the process of neuroendocrine differentiation. Int
J Cancer (2004) 111(4):508–13. doi:10.1002/ijc.20286
46. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with
a pleckstrin-homology domain, is an effector of phosphatidylinositol 3’-
kinase and is involved in interleukin 6-induced neuroendocrine differentia-
tion of prostate cancer cells. Proc Natl Acad Sci U S A (1998) 95(7):3644–9.
doi:10.1073/pnas.95.7.3644
47. Martin-Orozco RM, Almaraz-Pro C, Rodriguez-Ubreva FJ, Cortes MA, Ropero
S, Colomer R, et al. EGF prevents the neuroendocrine differentiation of LNCaP
cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia
(2007) 9(8):614–24. doi:10.1593/neo.07337
48. Cortes MA, Cariaga-Martinez AE, Lobo MV, Martin Orozco RM, Motino O,
Rodriguez-Ubreva FJ, et al. EGF promotes neuroendocrine-like differentiation
of prostate cancer cells in the presence of LY294002 through increased ErbB2
expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Carcinogenesis (2012) 33(6):1169–77. doi:10.1093/carcin/bgs139
49. Humez S, Monet M, Legrand G, Lepage G, Delcourt P, Prevarskaya N. Epi-
dermal growth factor-induced neuroendocrine differentiation and apoptotic
resistance of androgen-independent human prostate cancer cells. Endocr Relat
Cancer (2006) 13(1):181–95. doi:10.1677/erc.1.01079
50. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, et al. Varia-
tion in chromogranin A serum levels during intermittent versus continuous
androgen deprivation therapy for prostate adenocarcinoma. Prostate (2003)
55(3):168–79. doi:10.1002/pros.10222
51. Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, et al. Chromo-
granin A expression in patients with hormone naive prostate cancer predicts the
development of hormone refractory disease. J Urol (2007) 178(3 Pt 1):838–43.
doi:10.1016/j.juro.2007.05.018
52. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differen-
tiation in hormone refractory prostate cancer following androgen deprivation
therapy. Eur Urol (2004) 45(5):586–92. doi:10.1016/j.eururo.2003.11.032
53. Sarkar D, Singh SK, Mandal AK, Agarwal MM, Mete UK, Kumar S, et al.
Plasma chromogranin A: clinical implications in patients with castrate resis-
tant prostate cancer receiving docetaxel chemotherapy. Cancer Biomark (2010)
8(2):81–7. doi:10.3233/CBM-2011-0198
54. Burgio SL, ConteducaV, Menna C, Carretta E, Rossi L, Bianchi E, et al. Chromo-
granin A predicts outcome in prostate cancer patients treated with abiraterone.
Endocr Relat Cancer (2014) 21(3):487–93. doi:10.1530/ERC-14-0071
55. Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, et al. Chro-
mogranin A is a potential prognostic marker in prostate cancer patients treated
with enzalutamide. Prostate (2014) 74(16):1691–6. doi:10.1002/pros.22890
56. Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Receptor pro-
tein tyrosine phosphatase alpha signaling is involved in androgen depletion-
induced neuroendocrine differentiation of androgen-sensitive LNCaP human
prostate cancer cells. Oncogene (2003) 22(43):6704–16. doi:10.1038/sj.onc.
1206764
57. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, et al.
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration
of prostate cancer cells. Mol Cancer (2010) 9:55. doi:10.1186/1476-4598-9-55
58. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, et al.
Androgen deprivation induces human prostate epithelial neuroendocrine dif-
ferentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006)
13(1):151–67. doi:10.1677/erc.1.01043
59. Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M,
et al. Adrenomedullin, an autocrine/paracrine factor induced by androgen
withdrawal, stimulates ‘neuroendocrine phenotype’ in LNCaP prostate tumor
cells. Oncogene (2008) 27(4):506–18. doi:10.1038/sj.onc.1210656
60. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van
der Kwast TH, et al. Different profiles of neuroendocrine cell differentiation
evolve in the PC-310 human prostate cancer model during long-term andro-
gen deprivation. Prostate (2002) 50(4):203–15. doi:10.1002/pros.10049
61. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the
CWR22 human prostate cancer xenograft: association with tumor cell prolifer-
ation prior to recurrence. Prostate (2004) 60(2):91–7. doi:10.1002/pros.20032
62. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der
Kwast TH, et al. Androgen deprivation of the PC-310 [correction of prohor-
mone convertase-310] human prostate cancer model system induces neuroen-
docrine differentiation. Cancer Res (2000) 60(3):741–8.
63. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ,
van der Kwast TH, et al. Kinetics of neuroendocrine differentiation in an
androgen-dependent human prostate xenograft model. Am J Pathol (1999)
154(2):543–51. doi:10.1016/S0002-9440(10)65300-X
64. Noordzij MA, van Weerden WM, de Ridder CM, van der Kwast TH, Schroder
FH, van Steenbrugge GJ. Neuroendocrine differentiation in human prostatic
tumor models. Am J Pathol (1996) 149(3):859–71.
Frontiers in Oncology | Genitourinary Oncology April 2015 | Volume 5 | Article 90 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hu et al. Radiation-induced neuroendocrine differentiation in prostate cancer
65. Lin D,Wyatt AW, Xue H,Wang Y, Dong X, Haegert A, et al. High fidelity patient-
derived xenografts for accelerating prostate cancer discovery and drug devel-
opment. Cancer Res (2014) 74(4):1272–83. doi:10.1158/0008-5472.CAN-13-
2921-T
66. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, et al. Ionizing radia-
tion induces prostate cancer neuroendocrine differentiation through interplay
of CREB and ATF2: implications for disease progression. Cancer Res (2008)
68(23):9663–70. doi:10.1158/0008-5472.CAN-08-2229
67. Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, et al. Ioniz-
ing radiation induces neuroendocrine differentiation of prostate cancer cells
in vitro, in vivo and in prostate cancer patients. Am J Cancer Res (2011)
1(7):834–44.
68. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, et al.
Selective expression of CD44, a putative prostate cancer stem cell marker,
in neuroendocrine tumor cells of human prostate cancer. Prostate (2009)
69(7):787–98. doi:10.1002/pros.20928
69. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA(-/lo) prostate
cancer cell population harbors self-renewing long-term tumor-propagating
cells that resist castration. Cell Stem Cell (2012) 10(5):556–69. doi:10.1016/j.
stem.2012.03.009
70. Kyjacova L, Hubackova S, Krejcikova K, Strauss R, Hanzlikova H, Dzijak
R, et al. Radiotherapy-induced plasticity of prostate cancer mobilizes stem-
like non-adherent, Erk signaling-dependent cells. Cell Death Differ (2014).
doi:10.1038/cdd.2014.97
71. McKeithen D, Graham T, Chung LW, Odero-Marah V. Snail transcription fac-
tor regulates neuroendocrine differentiation in LNCaP prostate cancer cells.
Prostate (2010) 70(9):982–92. doi:10.1002/pros.21132
72. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, et al. Notch sig-
naling modulates hypoxia-induced neuroendocrine differentiation of human
prostate cancer cells. Mol Cancer Res (2012) 10(2):230–8. doi:10.1158/1541-
7786.MCR-11-0296
73. Luo Y, Lan L, Jiang YG, Zhao JH, Li MC, Wei NB, et al. Epithelial-mesenchymal
transition and migration of prostate cancer stem cells is driven by cancer-
associated fibroblasts in an HIF-1alpha/beta-catenin-dependent pathway. Mol
Cells (2013) 36(2):138–44. doi:10.1007/s10059-013-0096-8
74. Marhold M, Tomasich E, El-Gazzar A, Heller G, Spittler A, Horvat R, et al. HIF-
1alpha regulates mTOR signaling and viability of prostate cancer stem cells.Mol
Cancer Res (2014) 13(3):556–64. doi:10.1158/1541-7786.MCR-14-0153-T
75. Bhoumik A, Ronai Z. ATF2: a transcription factor that elicits oncogenic
or tumor suppressor activities. Cell Cycle (2008) 7(15):2341–5. doi:10.4161/
cc.6388
76. Lau E, Ronai ZA. ATF2 - at the crossroad of nuclear and cytosolic functions.
J Cell Sci (2012) 125(Pt 12):2815–24. doi:10.1242/jcs.095000
77. Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD. Mutual regulation of c-
Jun and ATF2 by transcriptional activation and subcellular localization. EMBO
J (2006) 25(5):1058–69. doi:10.1038/sj.emboj.7601183
78. Hsu CC, Hu CD. Critical role of N-terminal end-localized nuclear export
signal in regulation of activating transcription factor 2 (ATF2) subcellular
localization and transcriptional activity. J Biol Chem (2012) 287(11):8621–32.
doi:10.1074/jbc.M111.294272
79. Canaff L, Bevan S,Wheeler DG, Mouland AJ, Rehfuss RP,White JH, et al. Analy-
sis of molecular mechanisms controlling neuroendocrine cell specific tran-
scription of the chromogranin A gene. Endocrinology (1998) 139(3):1184–96.
doi:10.1210/en.139.3.1184
80. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor
activated by a diverse array of extracellular signals. Annu Rev Biochem (1999)
68:821–61. doi:10.1146/annurev.biochem.68.1.821
81. Suarez CD, Deng X, Hu CD. Targeting CREB inhibits radiation-induced
neuroendocrine differentiation and increases radiation-induced cell death in
prostate cancer cells. Am J Cancer Res (2014) 4(6):850–61.
82. Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD, Vinson C. A
dominant-negative inhibitor of CREB reveals that it is a general medi-
ator of stimulus-dependent transcription of c-fos. Mol Cell Biol (1998)
18(2):967–77.
83. Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM,
et al. Defining the CREB regulon: a genome-wide analysis of transcription
factor regulatory regions. Cell (2004) 119(7):1041–54. doi:10.1016/j.cell.2004.
10.032
84. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for can-
cer therapy: friend or foe. Curr Cancer Drug Targets (2010) 10(4):384–91.
doi:10.2174/156800910791208535
85. Groner B, Weiss A. Targeting survivin in cancer: novel drug development
approaches. BioDrugs (2014) 28(1):27–39. doi:10.1007/s40259-013-0058-x
86. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, et al. NE-
10 neuroendocrine cancer promotes the LNCaP xenograft growth in cas-
trated mice. Cancer Res (2004) 64(15):5489–95. doi:10.1158/0008-5472.CAN-
03-3117
87. Amorino GP, Deeble PD, Parsons SJ. Neurotensin stimulates mitogenesis of
prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene (2007)
26(5):745–56. doi:10.1038/sj.onc.1209814
88. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal
models of human prostate cancer: the consensus report of the New York meet-
ing of the mouse models of human cancers consortium prostate pathology
committee. Cancer Res (2013) 73(9):2718–36. doi:10.1158/0008-5472.CAN-
12-4213
89. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO,
et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995)
92(8):3439–43. doi:10.1073/pnas.92.8.3439
90. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, et al.
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of
neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell
(2010) 18(1):23–38. doi:10.1016/j.ccr.2010.05.024
91. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous
role of PTEN in regulating castration-resistant prostate cancer growth. Cancer
Cell (2011) 19(6):792–804. doi:10.1016/j.ccr.2011.05.006
92. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-
specific deletion of the murine Pten tumor suppressor gene leads to metastatic
prostate cancer. Cancer Cell (2003) 4(3):209–21. doi:10.1016/S1535-6108(03)
00215-0
93. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Wal-
dum HL. Neuroendocrine differentiation in carcinomas of the prostate:
do neuroendocrine serum markers reflect immunohistochemical findings?
Prostate (1997) 30(1):1–6. doi:10.1002/(SICI)1097-0045(19970101)30:1<1:
:AID-PROS1>3.3.CO;2-B
94. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circu-
lating neuroendocrine markers in patients with prostate carcinoma. Cancer
(2000) 88(11):2590–7. doi:10.1002/1097-0142(20000601)88:11<2590::AID-
CNCR23>3.0.CO;2-D
95. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, et al. Changes
in chromogranin a serum levels during endocrine therapy in metastatic
prostate cancer patients. Eur Urol (2005) 48(2):224–9. doi:10.1016/j.eururo.
2005.03.017
96. D’Amico A. Radiation and hormonal therapy for locally advanced and clin-
ically localized prostate cancer. Urology (2001) 58(2 Suppl 1):78–82. doi:10.
1016/S0090-4295(01)01246-8
97. Pollack A, Kuban DA, Zagars GK. Impact of androgen deprivation therapy on
survival in men treated with radiation for prostate cancer. Urology (2002) 60(3
Suppl 1):22–30. doi:10.1016/S0090-4295(02)01564-9
98. D’Amico AV. Radiation and hormonal therapy for locally advanced and clini-
cally localized prostate cancer.Urology (2002) 60(3 Suppl 1):32–7. doi:10.1016/
S0090-4295(02)01566-2
99. Lee WR. The role of androgen deprivation therapy combined with prostate
brachytherapy. Urology (2002) 60(3 Suppl 1):39–44. doi:10.1016/S0090-
4295(02)01568-6
100. Pollack A, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, et al.
Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat
Oncol Biol Phys (2001) 51(4):1002–7. doi:10.1016/S0360-3016(01)01750-3
101. Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life, and
cancer control outcomes after 3D conformal, intensity-modulated, and proton
radiation therapy for prostate cancer. SeminRadiatOncol (2013) 23(3):182–90.
doi:10.1016/j.semradonc.2013.01.004
102. Pugh TJ, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE. Radiation therapy
modalities in prostate cancer. J Natl Compr Canc Netw (2013) 11(4):414–21.
103. Mishra MV, Showalter TN. Pushing the limits of radiation therapy for
prostate cancer: where do we go next? Semin Oncol (2013) 40(3):297–307.
doi:10.1053/j.seminoncol.2013.04.005
www.frontiersin.org April 2015 | Volume 5 | Article 90 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hu et al. Radiation-induced neuroendocrine differentiation in prostate cancer
104. Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN,
Hurwitz MD, et al. Evolution of advanced technologies in prostate
cancer radiotherapy. Nat Rev Urol (2013) 10(10):565–79. doi:10.1038/nrurol.
2013.185
105. Koontz BF, Bossi A, Cozzarini C, Wiegel T, D’Amico A. A systematic review
of hypofractionation for primary management of prostate cancer. Eur Urol
(2014). doi:10.1016/j.eururo.2014.08.009
106. Morton GC. High-dose-rate brachytherapy boost for prostate cancer: rationale
and technique. J Contemp Brachytherapy (2014) 6(3):323–30. doi:10.5114/jcb.
2014.45759
107. Gray PJ, Efstathiou JA. Proton beam radiation therapy for prostate cancer-
is the hype (and the cost) justified? Curr Urol Rep (2013) 14(3):199–208.
doi:10.1007/s11934-013-0320-2
108. Efstathiou JA, Gray PJ, Zietman AL. Proton beam therapy and localised prostate
cancer: current status and controversies. Br J Cancer (2013) 108(6):1225–30.
doi:10.1038/bjc.2013.100
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 14December 2014; accepted: 26March 2015; published online: 14 April 2015.
Citation: Hu C-D, Choo R and Huang J (2015) Neuroendocrine differentiation in
prostate cancer: a mechanism of radioresistance and treatment failure. Front. Oncol.
5:90. doi: 10.3389/fonc.2015.00090
This article was submitted to Genitourinary Oncology, a section of the journal Frontiers
in Oncology.
Copyright © 2015 Hu, Choo and Huang . This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Oncology | Genitourinary Oncology April 2015 | Volume 5 | Article 90 | 10
